Kennedy faces sharp questioning on vaccines, pledges to prioritize chronic disease if confirmed as HHS secretary

Robert F. Kennedy Jr., President Trump’s nominee for secretary of the U.S. Department of Health and Human Services, faced sustained questioning from senators at a Senate Health, Education, Labor, and Pensions Committee hearing about his past statements on vaccines and how he would run the department if confirmed.

Committee members pressed Kennedy for unequivocal answers on whether commonly used vaccines cause autism, whether he would adhere to consensus science at HHS agencies, and how he would balance immediate infectious-disease priorities with a stated focus on preventing chronic disease. Kennedy repeatedly said he is "pro safety" and "pro good science," promised to implement President Trump’s policies if confirmed and told senators that if peer-reviewed data showed he was wrong he would apologize.

The hearing mattered because the HHS secretary oversees agencies that set vaccine policy, distribute federal health funds and run major public-health programs. Several senators warned that a lack of clear endorsements of established vaccine science at the department’s helm could weaken public trust and reduce vaccine uptake, with potentially lethal consequences for children and other vulnerable groups.

Key exchanges and commitments

Sen. Bill Cassidy (R-La.), committee chairman and a physician, repeatedly pressed Kennedy for a straight answer on whether measles and hepatitis B vaccines cause autism. Kennedy said, "If the data is there, I will absolutely do that," and added he would apologize for any prior statements that misled people. He told the panel he would not enter HHS with preordained views and said he would empower agency scientists.

Kennedy said he filed a lawsuit seeking revocation of the Food and Drug Administration’s emergency use for COVID-19 vaccines for certain children because, he said, the FDA recommended vaccination of 6‑year‑old children "without any evidence that it would benefit them and without testing on 6 year old children." He also said he represented plaintiffs in litigation alleging injury from the HPV (Gardasil) vaccine and that those matters are being litigated.

Ranking Member Sen. Bernie Sanders (I‑Vt.) and multiple Democrats pressed Kennedy on the practical consequences of his public statements. Sanders noted U.S. life‑expectancy and health disparities and asked whether Kennedy would defend policies that expand access to care and lower drug prices. Kennedy said he would implement the president’s policies and repeated he intends to pursue a prevention‑focused agenda to reduce chronic disease, including examining food additives and conflicts of interest in advisory panels.

Several senators demanded concrete guarantees about agency operations. Kennedy committed on the record to: not impound or divert appropriated vaccine program funds; not impose new grant conditions outside congressional direction to restrict access to vaccines or vaccine promotion programs; and to defend compliance with laws such as EMTALA (emergency medical treatment requirements) in emergency care settings when asked. He also said he would implement the president's positions on issues including Title X and chemical abortion policy.

Scientific monitoring and surveillance

Lawmakers pressed Kennedy about post‑approval vaccine monitoring systems. He referenced VAERS and the Vaccine Safety Datalink and said he wanted "gold standard" science and to remove conflicts of interest from advisory panels. Several senators — including Sen. Tammy Baldwin (D‑Wis.) and Sen. Richard Blumenthal (D‑Conn.) — recited the existing post‑market surveillance tools (VAERS, V‑SD, V‑Safe, and CISA) and urged Kennedy to rely on those systems and widely accepted peer‑reviewed evidence.

Concerns raised by senators

Democrats and some Republicans recited past statements and writings by Kennedy that they said undermined public confidence in vaccines — including comparisons and rhetoric that senators described as incendiary — and said those statements made it difficult to trust him as the nation’s top public‑health official. Sen. Edward Markey (D‑Mass.) and other senators cited Kennedy’s involvement in outreach to Samoa during that nation’s measles outbreak and said public messaging there had discouraged vaccination.

Other senators sought clarification on HHS program details after testimony in a prior hearing. Several raised concerns about Kennedy’s knowledge of Medicare and Medicaid operations; he acknowledged earlier misstatements and said he would work to learn department functions and implement the law and presidential policy.

Policy agenda on chronic disease and other priorities

Kennedy emphasized chronic disease prevention as a central mission. He said the United States spends far more than peer countries on health care while having worse outcomes and described plans to scrutinize food additives, reduce conflicts on advisory panels, and support research into environmental causes of chronic conditions. He described support for farmers and an interest in shifting agricultural incentives away from chemically intensive production, and said he would prioritize resilience in drug manufacturing and public‑private partnerships to reduce shortages.

What Kennedy would and would not do

Kennedy repeatedly told senators he would implement President Trump’s policies and that he would not "impose [his] preordained opinions" on agency staff. He pledged to support vaccine development for threats such as avian influenza and said he would not deprioritize vaccine review or delay approvals relative to historical norms.

Hearing context and next steps

The hearing featured extended rounds of questioning from a large number of senators across party lines and included both detailed policy queries and sustained interrogation of Kennedy’s previous public statements. The committee took no vote during the session; senators will submit additional questions for the record. The committee indicated a deadline for follow‑up questions for the nominee.

Why it matters going forward

The nominee’s approach to vaccine science, agency independence, conflicts of interest and chronic‑disease strategy will shape HHS actions if he is confirmed. Several senators said clear, unequivocal endorsements of established science would be necessary to restore public trust; others said they were persuaded by Kennedy’s emphasis on prevention and his promise to rely on agency scientists. The committee’s recommendations and the Senate’s eventual confirmation vote will determine whether those commitments translate into departmental policy.